SAN DIEGO, December 7, 2016 /PRNewswire/ --
Regen BioPharma Inc. (OTCQB: RGBPP) In a recent study published in the International Journal of Molecular Sciences a team of scientists in Guangzhou, China have demonstrated that expression of NR2F6 in patients with early cervical cancer correlates with poor prognoses. These scientists tested for NR2F6 in patient's cervical cancer tissue as well as in the normal tissue surrounding each of their tumors.
"This is an interesting study and the first that I am aware of that has tested for NR2F6 in patients with cervical cancer," said Harry Lander, Ph.D., President and Chief Scientific Officer of Regen BioPharma, Inc. "What they found was that those patients who had high amounts of NR2F6 protein expressed in their tumors died much faster than those patients with low or no expression of NR2F6 protein. To me, this is an important validation of the role of NR2F6 in cancer in humans, rather than simply animal models, and implies that inhibiting NR2F6 may be beneficial for these patients. While the study didn't go into the mechanism of action, it did show clear correlation and statistical significance indicating that NR2F6 expression is a potential biomarker for early cervical cancer."
Regen BioPharma, Inc. is developing small molecule inhibitors and activators of NR2F6. Inhibitors (which inhibit the expression of NR2F6) are expected to be useful in the treatment of various cancers and activators (which activate the expression of NR2F6) in the treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis.
"This journal article provides empirical evidence that supports our belief that inhibiting NR2F6 is a key to treating cancer in patients," noted David Koos, Regen's Chairman & CEO. "Our company sees an opportunity to enhance both the longevity and quality of life through further developing its NR2F6 small molecule therapies for treating cancer and autoimmune diseases."
Regen is also party to an agreement whereby Zander Therapeutics, Inc. has been granted by Regen an exclusive worldwide right and license for the development and commercialization of NR2F6 intellectual property controlled by Regen for non-human veterinary therapeutic use. Controlling NR2F6 in dogs and cats may be effective in treating diseases such cancer and arthritis at the veterinary level.
Regen believes that, in addition to its human therapeutics which may be developed by Regen, licensing fees related to veterinary applications of NR2F6 which may be developed by Zander may provide an additional income stream to Regen.
Zander Therapeutics Inc. is a wholly owned subsidiary of Entest BioMedical Inc. (PINKS: ENTB). David R. Koos serves as Chairman and Chief Executive Officer of Regen, Entest Biomedical, Inc. and Zander Therapeutics.
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on gene silencing therapy and small molecule therapies for treating cancer, along with developing stem cell treatments for aplastic anemia and disorders of the bone marrow. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
About Zander Therapeutics Inc.:
Zander Therapeutics, Inc. is a veterinary biotechnology company that is wholly owned by Entest BioMedical Inc. (a publicly traded company -- PINK: ENTB). Zander is primarily focused on developing small molecule therapies for treating autoimmune disorders and canine cancer (dogs). Currently the Company is developing products treating blood disorders using small molecules based on NR2F6 under an exclusive license agreement for veterinary use from Regen BioPharma Inc. (OTCQB: RGBP), gene silencing for treating cancer with immunotherapy, modulating key molecular processes in cancer stem cell through its patent molecular targeting approaches and repairing damaged bone marrow in animals with aplastic anemia and bone marrow suppression due to side effects of chemotherapy/radiotherapy treated cancer patients.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Int. J. Mol. Sci. 2016, 17, 1694
SOURCE Regen BioPharma, Inc.